Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation

Overview

Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients

Full Title of Study: “Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2018

Detailed Description

This study is a perspective, single-arm and open-labeled investigation of the safety and preliminary efficacy of unilateral subretinal transplantation of fRPE cells in subjects with dry Age-Related Macular Degeneration and non-exudative AMD. The investigators will recruit and enroll 6 patients based on specific inclusive/exclusive criteria. Experimental and self-controlled eye will be determined based on best-corrected visual acuity (BCVA). The eye with BCVA of no more than 20/400 will be determined as experimental eye, which will be divided into 3 groups and undergo subretinal injection of 3 different dosages of fRPE cells (100.000, 200,000 or 500,000) respectively, while the other one (BCVA of more than or equal to 20/400) as control eye, will not receive the surgery.

fRPE cells will be obtained from the fetuses aborted in the Department of Obstetrics and Gynecology in Jiangsu Province Hospital from 2015 to 2018. The obtained fRPE cells will meet specific inclusive/exclusive criteria and conform to Good manufacturing practices (GMP). fRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.

Immunosuppressive agents will be administered orally to all subjects after transplantation. Dosage and time duration of immunosuppressive agents will be regulated strictly relying on the condition of immune rejection. Subjects will be monitored with ophthalmologic and systemic examinations frequently at regular post-transplant intervals after fRPE cell transplantation.

Interventions

  • Drug: fRPE cells
    • fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure

Arms, Groups and Cohorts

  • Experimental: fRPE cells
    • Subretinal transplantation of fRPE cells in experimental eye

Clinical Trial Outcome Measures

Primary Measures

  • Number of subjects with adverse events
    • Time Frame: Two years following transplantation
    • Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period.

Secondary Measures

  • Assessment of standardized ETDRS acuity testing
    • Time Frame: Two years following transplantation
    • ETDRS stands for Early Treatment Diabetic Retinopathy Study which is designed to accurately measure visual acuity via ETDRS Scoring.
  • Assessment of visual function changes
    • Time Frame: Two years following transplantation
    • Assessments will include fluorescein angiography, fundus photography, spectral domain ocular coherence tomography (SD-OCT), microperimetry and multifocal electroretinography.
  • Assessment of systemic condition
    • Time Frame: Two years following transplantation
    • Items will include vital signs, electrocardiogram, blood and urine routine examination, tumor marker.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of dry AMD or non-exudative AMD (geographical atrophy>250μm, involving central fovea of macular; or AMD with fibrous disciform scar and maintained stationary for at least 3 months)
  • Experimental eye with best-corrected visual acuity (BCVA) of no more than 20/400 and control eye with BCVA of more than or equal to 20/400
  • Patients are in good state
  • Patient understand and sign the consent form.

Exclusion Criteria

  • Blood routine examination is abnormal (hemoglobin<10gm/dL; blood platelet count<100k/mm³; neutrophil count<1000/mm³)
  • Blood biochemistry is abnormal (ALT/AST>1.5; creatinine>1.3mg/dL)
  • Experimental eye has optic nerve atrophy caused by glaucoma
  • Patients need cataract surgery within a year
  • Patients have received cataract surgery and other ocular surgery in recent 3 months
  • Experimental eye has retinal detachment, or has received retinal detachment surgery.
  • Patients with uveitis and other endophthalmitis
  • Patients with other ocular disease affecting vision.
  • Patients have participated in clinical study of ocular or systemic drug use in recent 6 months.
  • Patients with medical history of malignant cancer (except resected basal cell carcinoma and squamous-cell carcinoma).
  • Patients with medical history of myocardial infarction
  • Patient with diabetes
  • Patient with Parkinson disease or Alzheimer's disease
  • Patients are under the treatment of immunosuppressive agent (except intermittent, low-dose corticosteroid treatment).
  • Patients with other medical conditions that restricts the compliance and safety of patients, or affects experimental results.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • The First Affiliated Hospital with Nanjing Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Qinghuai Liu, M.D., Principal Investigator, The First Affiliated Hospital with Nanjing Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.